Top Markets
#1 Nesa Nesa +790.47%
#2 Cortex Cortex +68.40%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.57%
#4 QuantixAI QuantixAI +23.51%
#5 EXOD EXOD +22.78%
#6 BSquared Network BSquared Network +20.12%
#7 Pons Pons +16.84%
#8 Instadapp Instadapp +16.15%
#9 OpenEden OpenEden +14.69%
#10 The Black Bull The Black Bull +13.93%
Coin of the day
Nesa Nesa
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Prometheus Biosciences, Inc. Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.

RXDX
Pozycja w akcjach #3432
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Cena akcji
$199.92
Ostatnia synchronizacja: 2023-06-15
Kapitalizacja rynkowa
$5.39B
Zmiana (1 dzień)
0.09%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Prometheus Biosciences, Inc. (RXDX)

Kategoria

Healthcare
Historia stopy dywidendy dla Prometheus Biosciences, Inc. (RXDX)
Stopa dywidendy (TTM) dla Prometheus Biosciences, Inc. (symbol akcji: RXDX) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Prometheus Biosciences, Inc. (RXDX) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
Firma Stopa dywidendy Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH